Pharma Plc News Today

Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.

The global biotechnology market was valued at approximately $1.55 trillion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030, reaching a staggering...

Redx Pharma Plc (LON:REDX – Get Free Report) shares crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 13.67 ($0.17) and traded as high as GBX 33 ($0.42). Redx Pharma shares last traded at GBX 15 ($0.19), with a volume of 1,420,135 […]

Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in ...

Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug ...

Investegate announcements from Posting of Annual Report & Notice of AGM

Investegate announcements from N4 Pharma Webinar on SRI Collaboration

Join N4 Pharma Plc for a pre-recorded webinar on their recent Collaboration Agreement with SRI International Inc. Available on 7 May 2024 at 10:00 BST.

N4 Pharma Plc partners with SRI International to combine Nuvec® with FOX Three MGS, aiming to enhance nucleotide therapies for cancer and vaccines.

Investegate announcements from Collaboration Agreement with SRI International Inc